Myriad Genetics grants Solaiman 83,049 stock options

The option is scheduled to vest and become exercisable in full on November 6, 2029, subject to continued service through that date.

Available on EDGAR 11/09/2026 - 04:14 PM EST Accepted by SEC EDGAR 11/09/2026 - 04:13 PM EST Learn about SEC filing dates

Rhea-AI Filing Summary

Myriad Genetics granted Chief People Officer Shereen Solaiman a one-time non-qualified stock option covering 83,049 shares of common stock as a retention award. The option has an exercise price of $5.92 per share, equal to the closing price on November 6, 2026. It vests and becomes exercisable in full on November 6, 2029, subject to continued service through that date, and expires November 6, 2036.

Insider Trade Summary

Grant/Award: 83,049 shares

Grant/Award 1 txn

Insider Solaiman Shereen

Role Chief People Officer

Type	Security	Shares	Price	Value
Grant/Award	Time-Based Stock Option F1, F2	83,049	$0.00	$0.00

Holdings After Transaction: Time-Based Stock Option — 83,049 options (Direct)

Footnotes (2)

1. F1. Represents a one-time non-qualified stock option granted as a retention award under the Issuer's 2026 Employee, Director and Consultant Equity Incentive Plan (the "Plan"). The option vests and becomes exercisable in full on November 6, 2029, subject to the Reporting Person's continued service through that date and the terms and conditions of the Plan and the applicable award agreement.
2. F2. The exercise price equals the closing price of the Issuer's common stock on November 6, 2026, the grant date.

Key Figures

Shares covered by option: 83,049 shares Exercise price: $5.92 per share Full vesting and exercisability date: November 6, 2029 +1 more

4 metrics

Shares covered by option 83,049 shares One-time non-qualified stock option grant

Exercise price $5.92 per share Equal to the closing price on November 6, 2026

Full vesting and exercisability date November 6, 2029 Subject to continued service through that date

Option expiration date November 6, 2036 Option expiration

Key Terms

non-qualified stock option, retention award, exercise price

3 terms

non-qualified stock option financial

"one-time non-qualified stock option"

A non-qualified stock option (NSO) is a contract that lets an employee or service provider buy company shares at a fixed price for a set period, like a voucher to purchase stock later at today’s price. It matters to investors because exercising NSOs creates ordinary income for the holder and can increase share count, affecting a company’s earnings and ownership mix; think of it as a future sale that can dilute existing shareholders and has immediate tax consequences for the recipient.

retention award financial

"granted as a retention award"

exercise price financial

"The exercise price equals the closing price"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many MYGN stock options did Chief People Officer Shereen Solaiman receive?

Shereen Solaiman received a one-time non-qualified stock option covering 83,049 shares of common stock, with an exercise price of $5.92 per share.

When do Shereen Solaiman's MYGN options vest and expire?

The option vests and becomes exercisable in full on November 6, 2029, subject to continued service through that date and the terms of the plan and award agreement. It expires on November 6, 2036.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Solaiman Shereen

(Last) (First) (Middle)

322 NORTH 2200 WEST

(Street)

SALT LAKE CITY UTAH 84116

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
MYRIAD GENETICS INC [ MYGN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief People Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
11/06/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Time-Based Stock Option(1)	$5.92(2)	11/06/2026		A		83,049		11/06/2029	11/06/2036	Common Stock	83,049	$0	83,049	D

Explanation of Responses:

1. Represents a one-time non-qualified stock option granted as a retention award under the Issuer's 2026 Employee, Director and Consultant Equity Incentive Plan (the "Plan"). The option vests and becomes exercisable in full on November 6, 2029, subject to the Reporting Person's continued service through that date and the terms and conditions of the Plan and the applicable award agreement.

2. The exercise price equals the closing price of the Issuer's common stock on November 6, 2026, the grant date.

Remarks:

	By: Justin Hunter For: Shereen Solaiman	11/09/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)